Please login to the form below

Not currently logged in


This page shows the latest midostaurin news and features for those working in and with pharma, biotech and healthcare.

FDA fast-tracks Astellas' Rydapt rival

FDA fast-tracks Astellas' Rydapt rival

Astellas Pharma has claimed a fast-track designation in the US for its FLT3 inhibitor gilteritinib, a drug that could rival Novartis’budding $250m-plus product Rydapt (midostaurin).

Latest news

More from news
Approximately 3 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...